Related Experiment Video
Updated: Aug 11, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
Published on: February 4, 2014
[Clinical pharmacology of ondansetron]
1II Kliniki Chorób Wewnetrznych A.M., Lodzi.
Abstract:
Ondansetron (ODS) is a new carbazole which exerts selective and potent antagonism on serotoninergic neurotransmission at serotonin 3 (5-HT3) receptors. Animal and clinical studies show that ODS reduces the incidence and severity of nausea and vomiting induced by cytotoxic drugs and radiotherapy. The antiemetic properties of this agent have been determined in ferrets against the nausea and vomiting induced by cisplatin, cyclophosphamide and whole-body radiation. The current hypothesis is that there may be both a peripheral and a central site of action for ODS. The lack of antagonist activity on dopamine and other non 5-HT3 receptors indicates that, unlike metoclopramide, ODS will not cause extrapyramidal or other dose-limiting side effects. ODS is rapidly and completely absorbed when administered as a tablet. Preliminary data show that ondansetron can be combined with dexamethasone safely with enhanced antiemetic results.
Insights
Ondansetron effectively reduces chemotherapy-induced nausea and vomiting by blocking serotonin 5-HT3 receptors. This carbazole derivative shows promise for managing side effects from cancer treatments with minimal adverse effects.
Area of Science:
- Pharmacology
- Neuroscience
- Oncology
Context:
- Chemotherapy and radiotherapy often induce severe nausea and vomiting.
- Current antiemetic treatments may have dose-limiting side effects.
- Selective serotonin 5-HT3 receptor antagonism is a key target for antiemesis.
Purpose:
- To evaluate the antiemetic efficacy of ondansetron (ODS).
- To investigate the mechanism of action of ODS.
- To assess the safety profile of ODS compared to other antiemetics.
Summary:
- Ondansetron (ODS) is a potent and selective 5-HT3 receptor antagonist.
- Studies in animals and humans demonstrate ODS reduces nausea and vomiting from cytotoxic drugs and radiation.
- ODS acts both peripherally and centrally, with no observed dopamine antagonism, suggesting a lack of extrapyramidal side effects.
Impact:
- Ondansetron offers a new therapeutic option for managing treatment-induced emesis.
- The drug's safety profile may allow for improved patient tolerance and adherence to cancer therapies.
- Combination therapy with dexamethasone may enhance antiemetic outcomes.
More Related Videos
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
05:56Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...